Search Results - "Molloy, Eamonn S"
-
1
PML and rheumatology: the contribution of disease and drugs
Published in Cleveland Clinic journal of medicine (01-11-2011)“…Progressive multifocal leukoencephalopathy (PML), a rare, typically fatal, opportunistic infection caused by the JC virus, is becoming relevant to physicians…”
Get full text
Journal Article -
2
Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies
Published in Arthritis & rheumatology (Hoboken, N.J.) (01-09-2012)“…Objective To evaluate the association of progressive multifocal leukoencephalopathy (PML) with immunosuppressive therapy for autoimmune rheumatic diseases…”
Get full text
Journal Article -
3
Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines
Published in Irish journal of medical science (01-02-2019)“…Background Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease which can cause significant disability, morbidity, mortality, and…”
Get full text
Journal Article -
4
Ustekinumab in Giant Cell Arteritis: Comment on the Article by Matza et al
Published in Arthritis care & research (2010) (01-07-2021)Get full text
Journal Article -
5
Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer
Published in BMC cancer (26-06-2009)“…Prostaglandin E2 (PGE2) is the major product of Cyclooxygenase-2 (COX-2) in colorectal cancer (CRC). We aimed to assess PGE2 cell surface receptors (EP 1-4) to…”
Get full text
Journal Article -
6
The role of toll like receptors in giant cell arteritis
Published in Rheumatology (Oxford, England) (01-11-2016)“…GCA is a common primary systemic vasculitis that results in granulomatous inflammation of medium to large arteries. Both innate and adaptive immune mechanisms…”
Get full text
Journal Article -
7
Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial
Published in Seminars in arthritis and rheumatism (01-12-2018)“…Giant cell arteritis (GCA) is the most common form of systemic vasculitis. Glucocorticoids are an effective treatment but have significant adverse events and…”
Get full text
Journal Article -
8
Successful reconstruction of an ocular defect resulting from granulomatosis with polyangiitis, following treatment with rituximab
Published in American journal of ophthalmology case reports (01-06-2018)“…To report a unique case of orbital inflammatory disease which was ultimately diagnosed as granulomatosis with polyangitis (GPA) and thus successfully treated…”
Get full text
Journal Article -
9
Ustekinumab for the treatment of refractory giant cell arteritis
Published in Annals of the rheumatic diseases (01-08-2016)Get more information
Journal Article -
10
Response to: ustekinumab inhibits Th1 and Th17 polarisation in a giant-cell arteritis patient by Samson et al
Published in Annals of the rheumatic diseases (01-02-2018)Get more information
Journal Article -
11
Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis
Published in Annals of the rheumatic diseases (01-12-2018)“…The pathogenesis of giant cell arteritis (GCA) remains unclear. T 1 and T 17 pathways are implicated, but the proximal initiators and effector cytokines are…”
Get more information
Journal Article -
12
The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management
Published in Rheumatic diseases clinics of North America (01-02-2017)“…Progressive multifocal leukoencephalopathy (PML) is a rare, typically fatal, demyelinating central nervous system infection caused by reactivation of the John…”
Get full text
Journal Article -
13
IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation
Published in JCI insight (09-08-2018)“…Severe lung inflammation and alveolar hemorrhage can be life-threatening in systemic lupus erythematosus (SLE) patients if not treated early and aggressively…”
Get full text
Journal Article -
14
Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?
Published in Autoimmunity reviews (01-12-2008)“…Abstract Progressive multifocal leukoencephalopathy (PML) is a rare, frequently fatal, infectious complication occurring in immunocompromised patients. PML has…”
Get full text
Journal Article -
15
Peroneal neuropathy in giant cell arteritis
Published in Rheumatology (Oxford, England) (01-01-2017)Get full text
Journal Article -
16
Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases
Published in Arthritis and rheumatism (01-12-2009)“…Objective Progressive multifocal leukoencephalopathy (PML) is a rare, typically fatal, central nervous system demyelinating disease that results from…”
Get full text
Journal Article -
17
Basic calcium phosphate crystals: pathways to joint degeneration
Published in Current opinion in rheumatology (01-03-2006)“…PURPOSE OF REVIEWBasic calcium phosphate crystals have long been associated with rheumatic syndromes. Although an understanding of the molecular mechanisms…”
Get full text
Journal Article -
18
Diagnostic Utility of Computed Tomographic Angiography in Giant-Cell Arteritis
Published in Stroke (1970) (01-09-2018)“…BACKGROUND AND PURPOSE—The diagnosis of giant-cell arteritis (GCA) is challenging. Superficial temporal artery biopsy and ultrasound are positive in only 50%…”
Get full text
Journal Article -
19
Performance characteristics and predictors of temporal artery ultrasound for the diagnosis of giant cell arteritis in routine clinical practice in a prospective cohort
Published in Clinical and experimental rheumatology (01-03-2019)“…The diagnosis of giant cell arteritis (GCA) is primarily a clinical one. Temporal artery (TA) ultrasound (US) has been proposed as a new diagnostic tool. We…”
Get full text
Journal Article -
20
Targeted but not trouble-free: efalizumab and PML
Published in Nature reviews. Rheumatology (01-08-2009)“…In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and…”
Get full text
Journal Article